Agree on both counts it was probably undervalued (when it was in the 3 range) and is quite volatile in price though I don't know about "settling down in the 6's".
They touted patients continuing on therapy in open label extensions of past trials for some time so I don't make anything out of that.
I currently have no position. I don't see Fabry as enough to get them to profitability.
I have been out of the stock for some time but do follow it a little bit still. Among other things I want to see how the Chaperone+ERT looks in Pompe before reconsidering it.
Market Data 
Markets 
AI
